General MedicationsINTRAVENOUS, SUBCUTANEOUSStandard
ACTEMRA
TOCILIZUMAB
Standard Dose
162MG/0.9ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ACTEMRA is listed in Drugs@FDA under application 125472 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TOCILIZUMAB Form and strength INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 162MG/0.9ML Sponsor GENENTECH Submission history Latest submission status date: 2025-12-10 00:00:00.
Structured Monograph
Clinical summary
Approval overview ACTEMRA is listed in Drugs@FDA under application 125472 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TOCILIZUMAB Form and strength INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 162MG/0.9ML Sponsor GENENTECH Submission history Latest submission status date: 2025-12-10 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.